All News
How Age of Onset Affects Giant Cell Arteritis
d
MedPage Today
Giant cell arteritis (GCA) has a different phenotype when diagnosed late in life compared with earlier onset, a large Italian cohort study indicated.
Read Article
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
d
EurekAlert!
The commonly used Fracture Risk Assessment Tool (FRAX), which includes self-identified race and ethnicity information, and the Osteoporosis Self-Assessment Tool (OST), which does not, had suboptimal performance in determining major osteoporotic fracture risk across racial/ethnic categories in you
Read Article
The Burden of Chronic Pain in US Adults (2019-2020)
Analysis of National Health Interview Survey data shows that the incidence of chronic pain in the USA is high compared with other chronic diseases.
Read Article
Therapeutic Plasma Exchange: Core Curriculum 2023 - Comprehensive, full read overview from American Journal of Kidney diseases & the National Kidney Foundation https://t.co/rmwwj5gol3 https://t.co/XFRZyD6hV4
Links:
Dr. John Cush RheumNow ( View Tweet)
View our infographic from the #LupusEducatorsNetwork and discover how you can apply the concept of #DiseaseModification in #Lupus and #LupusNephritis to help treat patients in your clinical practice #SponsoredbyGSKUSMA
https://t.co/fzspfwarK4 https://t.co/jXNte7f0sY
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: RNL23 Vasculitis Faculty Panel Q&A
RheumNow Live 2023: Robert Spiera, MD, Hospital for Special Surgery Anisha Dua, MD, MPH, Northwestern University, Feinberg School of Medicine Carol Langford, MD, MHS, FACP
https://t.co/4ddqt2tAQ8 https://t.co/KIPp3rePpp
Links:
Dr. John Cush RheumNow ( View Tweet)
SURPASS: SEC vs ADA for axSpA
Outcome: %pts with no radiographic progression
Not benefit- Secukinumab not better than adalimumab
Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! #RNL2023 https://t.co/xlw4nzrwpm https://t.co/dhhLMFQnhI
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: GPA Treatment Choices
https://t.co/MU6gZrgYDr https://t.co/lT1jI9jGGS
Links:
Dr. John Cush RheumNow ( View Tweet)
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/rfANCLcZii https://t.co/OFuMGZSvhm
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk factors for radiographic progression:
Men ♂️
Smoking 🚬
Active inflammation🔥
Blue collar workers 💪
HLA-B27+ 💉
Pre-existing syndesmophyte 🩻
Atul Deodhar at #RNL2023 @RheumNow https://t.co/FcwrDtOG6I https://t.co/AvRpPrg1UK
Links:
Dr. John Cush RheumNow ( View Tweet)
BIOBADASER registry of 3,366 RA/AS/PsA pts on 1,2 bDMARDs saw Remission-related Biologic D/C by 80 pts (2.4%). D/C Factors: short Dz duration (OR: 0.95), no csDMARDs (OR:0.56), shorter use prior bDMARD. Less D/C w/ smoking & ACPA+ https://t.co/iUdU9iI4AZ https://t.co/TknRW6pnJR
Links:
Dr. John Cush RheumNow ( View Tweet)
INBUILD study was an all cause ILD nintedanib RCT (n=663). Subanalysis of 89 RA-ILD pts showed FVC decline (@ 52 wks) was −82.6 mL/yr on NIN vs −199.3 mL/yr on PBO (p=.037). NIN diarrhea in 62%; & AE discontinuation in 24% https://t.co/nWuGx6wjB2 https://t.co/LVwy1Z5TL3
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: POD 7: Spondyloarthritis Innovations https://t.co/eDZlgdeWGr
Dr. John Cush RheumNow ( View Tweet)
Dr. Atul Deodhar on AxSpA
- 5-40% of nr-axSpA progress to r-axSpA over 2-10 years
- is non-radiographic axSpA a misnomer?
@RheumNow #RNL2023 https://t.co/HaavCnplO0 https://t.co/3jQaxVfFBH
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/6iAXKfZvEY https://t.co/kxqbiXVd2w
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
Atul Deodhar:
Prevalence of AS is increasing!
Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/HnzRrKko75 https://t.co/CBbvFIbRoi
Links:
Dr. John Cush RheumNow ( View Tweet)
Allergic Drug-Induced Arthritis
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/iRqfkFu52z. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
https://t.co/lRBaXMAgz6 https://t.co/37gIHniIEi
Dr. John Cush RheumNow ( View Tweet)
Microbiome of Hip and Knee Osteoarthritis is not "Sterile"
NGS techniques show the presence of bacterial DNA in surgical specimens of hip and knee arthritis, from patients undergoing first-time total joint arthroplasty, reports a study.
https://t.co/FIUG73x21N https://t.co/kNHgKiuxHM
Links:
Dr. John Cush RheumNow ( View Tweet)
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA.
https://t.co/B3tApMEWI3 https://t.co/Qi3WQkwvRd
Links:
Dr. John Cush RheumNow ( View Tweet)
Medevil ruler Bermudo II ("The Gouty", in Spanish: "el Gotoso") was King of León & Galicia (982 to 999). Some campaigns were a success but he lost wars & reign, presumeably from severe gout & could no longer ride horseback, & had to travel by litter https://t.co/xxzRNUY2mv https://t.co/YQRwGixd4Y
Links:
Dr. John Cush RheumNow ( View Tweet)